Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
25.03. | Creative Medical Technology Holdings Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
22.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
22.03. | Creative Medical Technology Holdings Inc expected to post a loss of $1.13 a share - Earnings Preview | 1 | Reuters | ||
07.03. | Why Is Diabetes Focused Creative Medical Stock Surging On Thursday? | 2 | Benzinga.com | ||
07.03. | Creative Medical stock rallies for second day on FDA updates | 1 | Seeking Alpha | ||
07.03. | Creative Medical Technology gains FDA nod for T1D therapy | 1 | Investing.com | ||
07.03. | Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101 | 1 | Zacks | ||
07.03. | Viking Therapeutics, Creative Medical Technology, Aptorum Group among healthcare movers | 59 | Seeking Alpha | ||
07.03. | Creative Medical Technology Skyrockets on Word of New Diabetes Medication | - | Baystreet.ca | ||
07.03. | Creative Medical Announces FDA Authorization For Expanded Access For CELZ-201; Stock Up | 1 | RTTNews | ||
06.03. | Creative Medical stock rallies 18% on FDA orphan drug designation | 1 | Seeking Alpha | ||
06.03. | Creative Medical Receives FDA Orphan Drug Designation For CELZ-101; Stock Up In Pre-market | 1 | RTTNews | ||
06.03. | Creative Medical rises on FDA's 'orphan drug' tag for transplantation therapy | 1 | Reuters | ||
06.03. | FDA grants Orphan Drug status to CELZ-101 for diabetes treatment | 2 | Investing.com | ||
20.12.23 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
20.12.23 | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem For Addressing Chronic Lower Back Pain | 557 | ACCESSWIRE | PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial... ► Artikel lesen | |
19.12.23 | Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem For Addressing Chronic Lower Back Pain | 1 | Benzinga.com | ||
16.11.23 | Creative Medical Technology Holdings Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
11.11.23 | Creative Medical Technology Holdings Inc expected to post a loss of 86 cents a share - Earnings Preview | 1 | Reuters |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
EVOTEC | 9,895 | +1,59 % | Evotec: Crash geht weiter - Deutsche Bank sieht Kursverdoppler | Die Aktie der Evotec SE befindet sich weiterhin im freien Fall. Am Donnerstag, den 25. April 2024, verzeichnete sie im Nachmittagshandel einen Rückgang von rund drei Prozent. Diese Entwicklung steht... ► Artikel lesen | |
MORPHOSYS | 66,10 | -0,15 % | Novartis-Übernahme läuft: Verlust verzehnfacht: Morphosys muss "Karten auf den Tisch legen" | © Foto: Sven Hoppe/dpaDie geplante Übernahme durch Novartis sorgt für hohe Kosten und lassen die Verluste bei Morphosys explodieren. Für Unruhe sorgt ein Fachartikel zu Sicherheit des Krebsmedikaments... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,760 | -4,44 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 3,928 | +156,40 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
BIONTECH | 85,65 | +2,39 % | Verhaltene Impfstoff-Nachfrage: BioNTech-Konkurrent Moderna: Umsatz bricht um 91 Prozent ein | © Foto: picture alliance / Geisler-Fotopress | Christoph Hardt/Geisler-FotopresTrotz erneut gesunkener Erlöse hat Biotech-Unternehmen Moderna die Erwartungen der Analysten übertreffen können. Dennoch... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,650 | +3,72 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
MODERNA | 117,30 | +13,51 % | Opening Bell: Bitcoin, Apple, Moderna, Pfizer, NIO, Tesla, Peloton | Die Fed hat gestern nicht an der Zinsschraube gedreht. Sie bleiben bei 5,25 bis 5,5 Prozent. Zudem machte Powell klar, dass der nächste Zinsschritt sehr wahrscheinlich keine Zinserhöhung sein werde.... ► Artikel lesen | |
JANUX THERAPEUTICS | 58,67 | +0,82 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
CABALETTA BIO | 12,540 | +1,05 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,760 | +4,69 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
CULLINAN THERAPEUTICS | 27,360 | -2,63 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
ARVINAS | 32,550 | +0,22 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 8,760 | -0,79 % | Arcutis Biotherapeutics, Inc.: Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | ||
DYNE THERAPEUTICS | 26,000 | +0,66 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |